HRMY: חוב כולל להון Harmony Biosciences Holdings, Inc.

Steady demand for sleep disorder medications supports the share price of Harmony Biosciences (HRMY), as confirmed by the current total debt-to-equity ratio, which has stabilized at 0.23. The financial stability of Harmony Biosciences (HRMY) is based on an asset-light model utilizing outsourced production. Furthermore, the localization of processes within the US and the specific nature of orphan drugs minimize geopolitical risks, ensuring the reliability of the company's financing structure.

This ratio serves as a key marker of the company's financial stability and credit risk level. The metric compares total liabilities to equity, determining the business's degree of dependence on borrowed funds. By analyzing changes in the total debt-to-equity ratio, an investor assesses the balance between financial leverage and solvency. For Harmony Biosciences (HRMY), an increase in this indicator reflects a strategy of aggressive startup acquisitions. Thus, leverage becomes a tool for diversifying the product portfolio.